miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation" YONGIN, South Korea, April 25, 2024 /PRNewswire/ Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that the results of a clinical performance.
Medicines for Malaria Venture (MMV) and Novartis announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and therefore efficacy and safety.
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® to account for metabolic differences in babies under 5.
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether-.
Novartis Pharma AG: Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.